文献速递消化道肿瘤放疗

美国非转移性直肠腺癌患者短程放射治疗的应用情况

Utilization of short-course radiation therapy for patients with nonmetastatic rectal adenocarcinoma in the United States.
PubMed 文献 · Adv Radiat Oncol · 2018-08-06

基于美国国家癌症数据库2004至2014年数据,42,336例接受术前放疗后手术的非转移性直肠腺癌患者中,仅1.1%接受短程放疗(20-25 Gy,<7次),98.9%接受长程放疗(45-70 Gy,≥25次)。短程放疗组年龄更大、合并症更多、T分期更早、临床淋巴结阴性比例更高,病理完全缓解率更低(4.3% vs 6.9%,P<.001),环周切缘阳性率更高(8.3% vs 5.2%,P=.001),多因素分析显示放疗分割方式与总生存无显著关联。

要点

  • 美国非转移性直肠癌术前短程放疗使用率约1%(469/42,336)。
  • 短程放疗组病理完全缓解率4.3% vs 长程放疗组6.9%(P<.001)。
  • 短程放疗组环周切缘阳性率8.3% vs 长程放疗组5.2%(P=.001)。

核心结论

  • 在美国,仅约1%的术前治疗非转移性直肠癌患者使用短程放疗。
  • 近期完成的随机试验结果可能进一步影响美国及国外的实践模式。

研究设计与样本

  • 回顾性查询美国国家癌症数据库,纳入2004年至2014年间接受术前放疗后手术的非转移性直肠腺癌患者。
  • 比较短程放疗(20-25 Gy,<7次)与长程放疗(45-70 Gy,≥25次)患者的特征。
  • 采用单因素和多因素Cox回归分析评估与总生存相关的因素,并使用逆概率加权回归调整方法比较生存率。

主要发现

  • 共纳入42,336例患者,其中41,867例(98.9%)接受长程放疗,469例(1.1%)接受短程放疗。
  • 短程放疗组患者年龄更大、合并症更多、T分期更早、临床淋巴结阴性比例更高。
  • 短程放疗组更常见于学术中心、有医疗保险及未接受化疗的患者。
  • 短程放疗组病理完全缓解率更低(4.3% vs 6.9%,P<.001),环周切缘阳性率更高(8.3% vs 5.2%,P=.001)。
  • 多因素分析显示放疗分割方式与总生存无显著关联。

关键数值与推荐

  • 短程放疗定义为20-25 Gy分<7次。
  • 长程放疗定义为45-70 Gy分≥25次。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Preoperative short-course radiation therapy (SCRT) for patients with nonmetastatic rectal adenocarcinoma has been studied in European trials, but is not often used in the United States. We aim to describe the utilization of preoperative SCRT among patients with nonmetastatic rectal cancer in the National Cancer Database and describe factors associated with its use. METHODS AND MATERIALS: The National Cancer Database was queried for patients treated with preoperative radiation therapy followed by surgery for nonmetastatic rectal adenocarcinoma between 2004 and 2014. Patient, tumor, and treatment-related characteristics were compared between patients treated with SCRT (20-25 Gy in <7 fractions) and patients treated with long-course radiation therapy (45-70 Gy in ≥ 25 fractions). Univariate and multivariate Cox regression analyses were used to evaluate factors associated with overall survival. Survival rates were compared using an inverse-probability-weighted regression adjustment method. RESULTS: A total of 42,336 patients were included for analysis of which 41,867 patients (98.9%) were treated with long-course radiation therapy and 469 patients (1.1%) with SCRT. Patients treated with SCRT were older, had more comorbidities, had earlier T-stage, and were more likely to be clinically node-negative. Patients treated with SCRT were more likely to be treated at an academic center, have Medicare insurance, and be treated without chemotherapy. Patients treated with SCRT had lower pathological complete response rates (4.3% vs 6.9%; P < .001) and higher rates of positive circumferential resection margins (8.3% vs 5.2%; P = .001). On multivariate analysis, radiation fractionation was not significantly associated with overall survival. CONCLUSIONS: SCRT is used for only approximately 1% of patients treated preoperatively for nonmetastatic rectal cancer in the United States. The results of recently completed randomized trials may further inform patterns of practice in the United States and abroad.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Abdel-Rahman O, Elhalawani HM, Allen PK, et al. Utilization of short-course radiation therapy for patients with nonmetastatic rectal adenocarcinoma in the United States. Adv Radiat Oncol. 2018. PMID: 30370362. doi:10.1016/j.adro.2018.07.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。